ANUHPHRBSEAnuh Pharma LtdHighNeutral
Announced Wed, 20 May · 22:48 IST

The record date for dividend is fixed and is enclosed herewith

Ebitda Margin CompressionRelated Party TransactionsRevenue Growth 20pctResults View source PDF

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.2%1-day move
₹81.50
prior close
₹80.81
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.5-3.5-4.3-4.6-6.2-6.3-6.1-6.1-6.1-7.5-2.5-3.2-1.4
Up moveDown movePending
AI summary

Anuh Pharma Limited reported FY2026 audited results with revenue from operations at Rs 77,165.74 Lakhs, up 16.6% YoY from Rs 66,151.49 Lakhs. Profit after tax declined 13.3% to Rs 4,104.61 Lakhs from Rs 4,735.19 Lakhs in the prior year. EBITDA margin compressed to 8.56% from 10.64% in FY2025, indicating pressure on profitability. The Board recommended a final dividend of Rs 1.50 per equity share (30% payout on face value of Rs 5), subject to shareholder approval at the AGM on 12th August 2026. Record date for dividend eligibility is 5th August 2026. Statutory auditors issued an unmodified (clean) opinion. Nine promoter group members (holding ~0.95% total shares) have sought reclassification from Promoter to Public category.

Likely market impact

Revenue grew but profitability declined due to margin compression. The company maintains a clean audit opinion with no going concern issues. The dividend at 30% payout signals confidence, but the PAT decline and margin compression may concern investors focused on earnings growth.